Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2020-09-14 Regulatory Filings
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from Tarsus Pharmaceuticals, Inc. to the Securities and Exchange Commission (SEC) staff regarding comments on their Draft Registration Statement on Form S-1. The letter addresses specific SEC comments and the company's revisions to the Registration Statement, which is a filing used for securities registration, typically for an initial public offering (IPO) or other public offering. The presence of detailed responses to SEC comments on a Form S-1 draft registration statement clearly identifies this as a regulatory filing related to securities registration. It is not an annual report, earnings release, or any other financial report type. The document is a regulatory correspondence and does not contain financial statements or management discussion but is a formal regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement or report publication announcement but a substantive regulatory filing.
2020-09-14 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is a confidential amendment to a draft registration statement on Form S-1 submitted to the SEC by Tarsus Pharmaceuticals, Inc. The Form S-1 is used for initial public offerings (IPOs) to register securities under the Securities Act of 1933. The text includes detailed information typical of a prospectus, such as company overview, risk factors, use of proceeds, management discussion and analysis, executive compensation, and underwriting details. It is not a financial report like an annual or quarterly report, nor is it an earnings release or a regulatory filing unrelated to registration. The document is a registration statement for a securities offering, which falls under the category of Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes.
2020-09-14 English
Regulatory Filings 2020
Regulatory Filings
2020-09-04 English
Regulatory Filings 2020
Regulatory Filings
2020-09-04 English
Regulatory Filings 2020
Regulatory Filings Classification · 100% confidence The document is a confidential Amendment No. 1 to a draft registration statement on Form S-1 submitted to the SEC by Tarsus Pharmaceuticals, Inc. It is clearly identified as a registration statement under the Securities Act of 1933, which is used for registering securities for public offering. The document includes detailed information about indemnification of directors and officers, recent sales of unregistered securities, and exhibits related to corporate governance and underwriting agreements. There is no indication that this is a financial report, earnings release, or any other type of report listed in the filing definitions. Instead, it is a regulatory filing related to securities registration and offering. The document is not a report publication announcement since it contains substantive content and is not merely announcing the availability of a report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-08-14 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC by Tarsus Pharmaceuticals, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information about the company, its business, risk factors, management, financial data, and the offering terms. This type of filing is a registration statement for securities offering, not an annual report, earnings release, or other financial report. It is not a report publication announcement or a certification. The document is a primary registration filing for capital raising purposes under the Securities Act of 1933, which fits the Capital/Financing Update category.
2020-08-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.